Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Imaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast Tomosynthesis


Posted on: 08 Nov 17

Technology utilizes advanced artificial intelligence to improve speed and accuracy in the detection of breast cancer

KANSAS CITY, Mo., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Imaging for Women, a leading radiology center in Kansas City, Missouri, today announced that it is now using iCAD’s (NASDAQ:ICAD) PowerLook® Tomo Detection, an advanced artificial intelligence (AI) technology, to support faster and more accurate detection of breast cancer. PowerLook Tomo Detection is a first-of-its-kind, concurrent-read, cancer detection solution for digital breast 3D tomosynthesis (DBT), that provides significant advantages to both radiologists and patients.

In a U.S. clinical study conducted in 2016, radiologists were able to decrease reading time by up to 37 percent with an average reduction of 29 percent when using PowerLook Tomo Detection, with no statistically significant impact on sensitivity, specificity or recall rate.

“At Imaging for Women, we are dedicated to bringing our patients and community the most advanced technologies available today to support breast cancer detection,” said Phyllis Fulk, Administrator, Imaging for Women. “With iCAD’s PowerLook Tomo Detection, we are now able to take screening and diagnostic mammography to the next level, making it possible to improve detection with greater accuracy and more efficiency, without compromising clinical performance.”

Unlike 2D full-field digital mammography that typically produces four images per breast exam, tomosynthesis exams produce hundreds of images, often requiring radiologists to spend a significant amount of time reviewing and interpreting images. iCAD’s PowerLook Tomo Detection utilizes a trained algorithm developed through deep learning that automatically analyzes each plane in this vast data set, supporting radiologists in identifying questionable areas with greater speed and precision. Suspicious areas identified are then blended into a 2D synthetic image to provide radiologists with a single enhanced image.

“Our radiology team is thrilled with the unique capabilities and improved workflow iCAD’s AI breast cancer detection technology provides, said Mark Malley, M.D., Chief of Radiology, Imaging for Women. “I have a higher level of security that I haven’t missed any significant findings with the iCAD for tomosynthesis. This is a helpful tool in our diagnostic toolbox.”

About Imaging for Women

Imaging for Women opened in 1997 as Kansas City’s first stand-alone women’s imaging center because Dr. Mark Malley envisioned a better way for women to experience health care.  He wanted to extend high quality medicine to all women in the community. Dr. Malley gathered a staff of dedicated personnel with a genuine caring attitude and a zeal for outstanding health care.  Dr. Voeltz and Dr. Zupon continue to lead the practice with their passionate commitment to patient care.

Our Philosophy

Our goal is to offer the patient the best possible experience when they visit our facility. We accomplish this by both utilizing the best technology currently available, including 3-D mammography and whole breast ultrasound, and using certified technologists who are chosen for their skill at performing exams while showing compassion to the patient. The exam is read in real-time by one of our board certified physicians, who have specialty training in breast imaging.  If any additional images or exams are needed, they can be done the same day and the patient will leave knowing the results of the exam. If a biopsy or other special imaging is needed, the radiologist will discuss the need for this with the patient and in some cases the biopsy can be done the same day.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights,  product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:

For iCAD investor relations:
LifeSci Advisors
Bob Yedid, (646)-597-6989
Bob@lifesciadvisors.com

or

For iCAD media inquiries:
ARPR
Erin Bocherer, 678-294-2258
erin@arpr.com

GlobeNewswire
globenewswire.com

Last updated on: 08/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.